8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY
申请人:F. Hoffmann-La Roche AG
公开号:EP2773632B1
公开(公告)日:2017-04-12
US8669251B2
申请人:——
公开号:US8669251B2
公开(公告)日:2014-03-11
US8754077B2
申请人:——
公开号:US8754077B2
公开(公告)日:2014-06-17
[EN] 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY<br/>[FR] COMPOSÉS 8-FLUOROPHTALAZIN-1(2H)-ONE COMME INHIBITEURS DE L'ACTIVITÉ BTK
申请人:GENENTECH INC
公开号:WO2013067264A1
公开(公告)日:2013-05-10
8-Fluorophthalazin-1(2h)-one compounds of Formula (II) where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (II) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS
申请人:Genentech, Inc.
公开号:US20130116246A1
公开(公告)日:2013-05-09
8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X
1
, X
2
, and X
3
are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.